934-16-7

Usage

Uses

Used in Pharmaceutical Synthesis:
Phenylhydroxamoyl chloride is used as an intermediate in the synthesis of Oxacillin Sodium Salt (O758503), a narrow-spectrum beta-lactam antibiotic. It plays a crucial role in the production of this antibiotic, which is effective against a range of bacterial infections.
Used in Analytical Chemistry:
Phenylhydroxamoyl chloride is utilized in the analytical study of the combination of reversed phase liquid chromatography and zwitterion exchange-reversed phase-hydrophilic interaction mixed-mode liquid chromatography coupled with mass spectrometry for the analysis of antibiotics and their impurities. This application helps in the accurate determination and quantification of antibiotic compounds and their related substances, ensuring the quality and safety of pharmaceutical products.

Upstream product

• 90690-87-2 C₉H₇Cl₂NO₂ 
• 100-52-7 benzaldehyde 
• 622-32-2 (Z)-benzaldehyde oxime 
• 932-90-1 syn-benzaldehyde oxime 
• 932-90-1 Benzaldoxime 

Downstream Products

• 67503-14-4 3',4'-diphenyl-1H,4'H-spiro[indole-3,5'-[1,2,4]oxadiazol]-2-one 
• 67503-15-5 5-methyl-3',4'-diphenyl-1H,4'H-spiro[indole-3,5'-[1,2,4]oxadiazol]-2-one 
• 67503-19-9 5-nitro-3',4'-diphenyl-1H,4'H-spiro[indole-3,5'-[1,2,4]oxadiazol]-2-one 
• 67503-18-8 5-bromo-3',4'-diphenyl-1H,4'H-spiro[indole-3,5'-[1,2,4]oxadiazol]-2-one 
• 67503-17-7 5-fluoro-3',4'-diphenyl-1H,4'H-spiro[indole-3,5'-[1,2,4]oxadiazol]-2-one 
• 67503-16-6 4'-(4-fluoro-phenyl)-1-methyl-3'-phenyl-1H,4'H-spiro[indole-3,5'-[1,2,4]oxadiazol]-2-one 
• 111042-17-2 (Z)-Aziridinylbenzaldoxime 
• 104739-49-3 6a-Ethoxy-4,5,6,6a-tetrahydro-6-methyl-3-phenyl-3aH-pyrrolo<3,2-d>isoxazol 
• 82414-21-9 3-Phenyl-8,8a-dihydro-3aH-isoxazolo[5,4-b]indole 
• 82414-25-3 3-benzoylindole, Z-oxime 
• 86598-00-7 3,8b-Diphenyl-6,7,8a,8b-tetrahydro-5aH-thieno[2',3':4,5]isoxazolo[2,3-d][1,2,4]oxadiazole 8,8-dioxide 
• 86598-01-8 3-Phenyl-3a,4,5,6a-tetrahydro-thieno[3,2-d]isoxazole 6,6-dioxide 
• 86597-99-1 3-Phenyl-3a,5,6,6a-tetrahydro-thieno[2,3-d]isoxazole 4,4-dioxide 
• 61-70-1 N-methyl-2-indolinone 

Relevant academic research and scientific papers

Decarboxylative Alkylation of Heteroarenes Using N-Hydroxybenzimidoyl Chloride Esters

Functionalized N-heteroarenes are highly desired motifs in medicinal chemistry and pharmaceutical industry. Minisci-type reactions usually require a protonated N-heteroarene for the alkyl radical to attack. This work describes a leaving-group-assisted redox-active ester to enable direct coupling of an amino acid with N-heteroarenes. The efficient and sustainable photoredox strategy provides rapid access to an alkylated heterocyclic manifold.

Leaving Group Assisted Strategy for Photoinduced Fluoroalkylations Using N-Hydroxybenzimidoyl Chloride Esters

Redox-active esters (RAEs) as alkyl radical precursors have been extensively developed for C?C bond formations. However, the analogous transformations of fluoroalkyl radicals from the corresponding acid or ester precursors remain challenging because of the high oxidation potential of the fluoroalkyl carboxylate anions. The newly developed N-hydroxybenzimidoylchloride (NHBC) ester provides a general leaving group assisted strategy to generate a portfolio of fluoroalkyl radicals, and can be successfully applied in photoinduced decarboxylative hydrofluoroalkylation and heteroarylation of unactivated olefins. In addition, DFT calculations revealed that the NHBC ester proceeds by the fluorocarbon radical pathway, whereas other well-known RAEs proceed by the nitrogen radical pathway.

Terminal Alkyne-Assisted One-Pot Synthesis of Arylamidines: Carbon Source of the Amidine Group from Oxime Chlorides

A terminal alkyne-assisted protocol for the one-pot formation of a diverse range of arylamidines from a novel cascade reaction of in situ generated nitrile oxides, sulfonyl azides, terminal alkynes, and water by [3 + 2] cycloaddition and ring opening sequ

Valdecoxib: Vs. borazavaldecoxib: Isoxazole BN/CC isosterism as a case study in designing and stabilizing boron heterocycles

A comprehensive study on the preparation, hydrolytic stability, and the structural and spectrophotometric properties of 1,2,4,5-oxadiazaboroles is presented by way of a comparison between the NSAID drug valdecoxib (1) and its unprecedented B-N isostere, borazavaldecoxib (2). Knowledge gained from this study was employed in the design of oxadiazaborate salts, a novel class of tetrahedral boron heterocycles displaying good stability in aqueous conditions with promising antifungal and antibacterial properties.

Reaction between (Z)-Arylchlorooximes and α-Isocyanoacetamides: A procedure for the synthesis of Aryl-α-ketoamide amides

(Z)-Arylchlorooximes and α-isocyanoacetamides undergo a smooth reaction to produce 1,3-oxazol-2-oxime derivatives in good yields. Opening of the oxazole ring and deoximation reaction give a facile access to aryl-α-ketoamide amides, a class of privileged s

Isocyanide-mediated multicomponent synthesis of C-oximinoamidines

By capitalizing on the different reactivity of nitrile N-oxides with isocyanides and amine, α-oximinoamidines, a so far elusive class of compounds, have been synthesized in a straightforward way by reacting isocyanides, syn-chlorooximes, and amines in a multicomponent fashion.

HETEROCYCLIC COMPOUNDS AS S1P1 AGONISTS FOR THE TREATMENT OF AUTOIMMUNE AND VASCULAR DISEASES

Disclosed are compounds of Formula (I) or stereoisomers, salts, or prodrugs thereof, wherein: W is CH2 or O; Q is Formula (II), Formula (III) or Formula (IV); and R1, R2, R3, R4, n, and G are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

AMINOPYRAZINE COMPOUNDS USEFUL AS INHIBITORS OF TRA KINASE

The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds of this invention have formula (I): wherein the variables are as defined herein.

SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS

Disclosed are compounds of Formula (I), or a stereoisomer or a pharmaceutically acceptable salt thereof, wherein: A is formula (II) Q is a substituted 5-membered monocyclic heteroaryl group; W is CH2, O, or NH; and R1, R2, R3, R4, R5, R6, m, n, t, and x are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

TRICYCLIC HETEROCYCLIC COMPOUNDS

Disclosed are compounds of Formula (I) or stereoisomers or salts thereof, wherein: X1, X2, X3, W, Q1, Q2, and G2 are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.